Efficacy and Safety of Transarterial Therapies+Donafenib + Anti-PD-1 Antibody for uHCC: A Retrospective Real-world Study
NCT05638438
·
clinicaltrials.gov ↗
UNKNOWN
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma Non-resectable
Interventions
PROCEDURE:
transarterial therapies
Sponsor
Zhujiang Hospital